The emergence of INSM1 as a more sensitive “second-generation” biomarker for neuroendocrine differentiation in the breast holds promising prospects for improved diagnosis of breast NETs, which are difficult to distinguish from other types of breast carcinomas based on histologic features alone. Here, INSM1 is linked to breast carcinoma.